[1]
|
Friese M A,Hellwage J,Jokiranta T S,et al. Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA)[J]. Clin Exp Immunol,2000,121(2):406-415. doi: 10.1046/j.1365-2249.2000.01285.x
|
[2]
|
Jokiranta T S,Hellwage J,Koistinen V,et al. Each of the three binding sites on complement factor H interacts with a distinct site on C3b[J]. J Biol Chem,2000,275(36):27657-27662. doi: 10.1074/jbc.M002903200
|
[3]
|
Friese M A,Hellwage J,Jokiranta T S,et al. FHL-1/reconectin and factor H:two human complement regulators which are encoded by the same gene are differently expressed and regulated[J]. Mol Immunol,1999,36(13-14):809-818. doi: 10.1016/S0161-5890(99)00101-7
|
[4]
|
Rodriguez de Cordoba S,Esparza-Gordillo J,Goicoechea de Jorge E,et al. The human complement factor H:functional roles,genetic variations and disease associations[J]. Mol Immunol,2004,41(4):355-367. doi: 10.1016/j.molimm.2004.02.005
|
[5]
|
李建国,肖慧捷,杨霁云. 补体H因子研究进展[J]. 国外医学(儿科学分册),2005,32(3):143-146.
|
[6]
|
Cserhalmi M, Papp A, Brandus B, et al. Regulation of regulators: Role of the complement factor H-related proteins[J]. Semin Immunol, 2019, 45: 101341.
|
[7]
|
De Córdoba S R,De Jorge E G. Translational mini‐review series on complement factor H:genetics and disease associations of human complement factor H[J]. Clinical & Experimental Immunology,2008,151(1):1-13.
|
[8]
|
Parente R,Clark S J,Inforzato A,et al. Complement factor H in host defense and immune evasion[J]. Cell Mol Life Sci,2017,74(9):1605-1624. doi: 10.1007/s00018-016-2418-4
|
[9]
|
Laine M,Jarva H,Seitsonen S,et al. Y402H polymorphism of complement factor H affects binding affinity to creactive protein[J]. The Journal of Immunology,2007,178(6):3831-3836. doi: 10.4049/jimmunol.178.6.3831
|
[10]
|
Clark S J,Bishop P N. Role of factor H and related proteins in regulating complement activation in the macula,and relevance to age-related macular degeneration[J]. Journal of Clinical Medicine,2015,4(1):18-31.
|
[11]
|
Goodship T H,Cook H T,Fakhouri F,et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy:Conclusions from a “Kidney disease:Improving global outcomes”(KDIGO) controversies conference[J]. Kidney International,2017,91(3):539-551. doi: 10.1016/j.kint.2016.10.005
|
[12]
|
Montaniel K R,Harrison D G. Is hypertension a bone marrow disease?[J]. Circulation,2016,134(18):1369-1372. doi: 10.1161/CIRCULATIONAHA.116.024520
|
[13]
|
Ruan C C,Gao P J. Role of complement-related inflammation and vascular dysfunction in hypertension[J]. Hypertension,2019,73(5):965-971. doi: 10.1161/HYPERTENSIONAHA.118.11210
|
[14]
|
Fritsche L G,Lauer N,Hartmann A,et al. An imbalance of human complement regulatory proteins CFHR1,CFHR3 and factor H influences risk for age-related macular degeneration (AMD)[J]. Human Molecular Genetics,2010,19(23):4694-4704. doi: 10.1093/hmg/ddq399
|
[15]
|
Engström G,Hedblad B,Berglund G,et al. Plasma levels of complement C3 is associated with development of hypertension:A longitudinal cohort study[J]. Journal of Human Hypertension,2007,21(4):276-282. doi: 10.1038/sj.jhh.1002129
|
[16]
|
Chen L,Fukuda N,Matsumoto T,et al. Role of complement 3 in the pathogenesis of hypertension[J]. Hypertens Res,2020,43(4):255-262. doi: 10.1038/s41440-019-0371-y
|
[17]
|
Chen L,Fukuda N,Otsuki T,et al. Increased complement 3 with suppression of miR-145 Induces the synthetic phenotype in vascular smooth muscle cells from spontaneously hypertensive rats[J]. J Am Heart Assoc,2019,8(10):e012327.
|
[18]
|
Zhang C,Li Y,Wang C,et al. Complement 5a receptor mediates angiotensin II–Induced cardiac inflammation and remodeling[J]. Arteriosclerosis,Thrombosis,and Vascular Biology,2014,34(6):1240-1248. doi: 10.1161/ATVBAHA.113.303120
|
[19]
|
GAN W,WU J,LU L,et al. Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population[J]. PloS One,2012,7(7):e42010. doi: 10.1371/journal.pone.0042010
|
[20]
|
Wong T Y,Tikellis G,Sun C,et al. Age-related macular degeneration and risk of coronary heart disease:The atherosclerosis risk in communities study[J]. Ophthalmology,2007,114(1):86-91. doi: 10.1016/j.ophtha.2006.06.039
|
[21]
|
Hageman G S,Anderson D H,Johnson L V,et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration[J]. Proceedings of the National Academy of Sciences,2005,102(20):7227-7232.
|
[22]
|
Klein R,Knudtson M D,Klein B E,et al. Inflammation,complement factor h,and age-related macular degeneration:the Multi-ethnic Study of Atherosclerosis[J]. Ophthalmology,2008,115(10):1742-1749. doi: 10.1016/j.ophtha.2008.03.021
|
[23]
|
Giannakis E,Male D,Ormsby R,et al. Multiple ligand binding sites on domain seven of human complement factor H[J]. Int. Immunopharmacol,2001,1(3):433-443. doi: 10.1016/S1567-5769(00)00040-0
|
[24]
|
Pai J K,Manson J E,Rexrode K M,et al. Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women[J]. European Heart Journal,2007,28(11):1297-1303. doi: 10.1093/eurheartj/ehm090
|
[25]
|
孙彩琴,陈忠,马根山,等. 早发冠心病患者血浆补体因子H浓度检测及其临床意义[J]. 实用临床医药杂志,2008,12(1):88-89. doi: 10.3969/j.issn.1672-2353.2008.01.024
|
[26]
|
钱琦,陈忠,马根山,等. 血浆补体因子H、超敏C反应蛋白和胰岛素抵抗与冠心病的关系[J]. 江苏医药,2009,35(4):382-384.
|
[27]
|
Nicaud V,Francomme C,Ruidavets J-B,et al. Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction[J]. Journal of Molecular Medicine,2007,85(7):771-775. doi: 10.1007/s00109-007-0185-2
|
[28]
|
孙彩琴,陈忠,马根山. 补体因子H基因^127T/C多态性与早发冠心病的相关性研究[J]. 交通医学,2008,22(6):606-608. doi: 10.3969/j.issn.1006-2440.2008.06.005
|
[29]
|
Yndestad A,Damas J K,Qie E,et al. Role of inflammation in the progression of heart failure[J]. Current Cardiology Reports,2007,9(3):236-241. doi: 10.1007/BF02938356
|
[30]
|
Suffritti C,Tobaldini E,Schiavon R,et al. Complement and contact system activation in acute congestive heart failure patients[J]. Clinical & Experimental Immunology,2017,190(2):251-257.
|
[31]
|
Shahini N,Michelsen A E,Nilsson P H,et al. The alternative complement pathway is dysregulated in patients with chronic heart failure[J]. Scientific Reports,2017,7(42532):2045-2322.
|
[32]
|
Hovland A,Jonasson L,Garred P,et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis[J]. Atherosclerosis,2015,241(2):480-494. doi: 10.1016/j.atherosclerosis.2015.05.038
|
[33]
|
Ge X,Xu C,Liu Y,et al. Complement activation in the arteries of patients with severe atherosclerosis[J]. Int J Clin Exp Pathol,2018,11(1):1-9.
|
[34]
|
An G,Li B,Liu X,et al. Overexpression of complement component C5a accelerates the development of atherosclerosis in ApoE-knockout mice[J]. Oncotarget,2016,7(35):56060-56070. doi: 10.18632/oncotarget.11180
|